Sophiris says it’s ready to get back on track with lead drug af­ter pa­tient death — but ques­tions linger

Sophiris’ shares $SPHS took a beat­ing two months ago when the biotech dis­closed that a pa­tient died on the same day of a sec­ond ad­min­is­tra­tion of their drug top­salysin in a Phase IIb prostate can­cer tri­al.

That death caused the biotech to put a brake on their dos­ing plans. Now, they’d like to wipe the slate clean of any nag­ging safe­ty is­sues.

In a new state­ment out this morn­ing, the San Diego-based biotech says the re­searchers in­volved have con­clud­ed that their pa­tient had like­ly died as a re­sult of “sud­den car­diac death prob­a­bly due to an ar­rhyth­mia…The in­ves­ti­ga­tor and the com­pa­ny con­cur that the event is un­like­ly re­lat­ed to top­salysin or the pro­ce­dure.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.